Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
News|Articles|June 23, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016
- Volume 11
- Issue 7
Dow Launches ETHOCEL HP
Author(s)Pharmaceutical Technology Editors
ETHOCEL HP is a solvent free advanced productivity technology for barrier membrane coating.
Advertisement
Dow Pharma & Food Solutions, a division of Dow Chemical Company, announced the global launch and commercial availability of ETHOCEL High Productivity (HP), a ethylcellulose polymer for multiparticulate and taste-masking applications, designed specifically for use with rotor coater systems. The product is commercially available exclusively through Colorcon Inc, as part of the Dow and Colorcon Controlled Release Alliance, Dow said in a June 21, 2016
Dry coating with ETHOCEL HP offers shorting coating times for barrier membranes, at higher efficiencies, and without the need for solvents. ETHOCEL HP has shown a step improvement in coating time, 70% faster than traditional solvent and aqueous spray coating systems, according to trials conducted by Dow. Removing the solvent from the coating process allows opportunities for cost reduction and improved operation safety, the company noted.
Source:
Articles in this issue
over 10 years ago
Potential Consequences of the CDMO Acquisition Bingeover 10 years ago
Flow Chemistry Discoveries Advance Continuous Processingover 10 years ago
Excipient Quality Essentialsover 10 years ago
CordenPharma Expands Service Offeringsover 10 years ago
Real-time Monitoring Systems for Drug Shipmentsover 10 years ago
Vessel Improves Dissolution Test Resultsover 10 years ago
Pump Designed for Continuous Processing Scale-upover 10 years ago
Juniper Pharma Services Adds Tablet Pressover 10 years ago
Recipharm Expands Serialization Capabilitiesover 10 years ago
Charles River Acquires Blue Stream LaboratoriesAdvertisement
Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5